United States: Pro Te: Solutio – Winter 2016


By Kim Coggin

Before a research site begins work on a sponsor-initiated clinical trial, the sponsor and the site should enter into a "clinical trial agreement" or "CTA," to establish the obligations of each party, to convey certain rights to each party, and to allocate risks between the parties. Typically, the sponsor provides its CTA template to the site for review, and the parties will proceed to negotiate the CTA – with each side looking to lock in terms favorable to it.

Each CTA negotiation presents its own unique set of challenges. However, virtually every one will devote significant time to the following issues: ownership and use of trial data, intellectual property, publications, and trial participant injury. Parties often dig in their heels on these provisions without fully understanding these issues or their importance within the context of clinical trial setting. The resulting delays can be detrimental to the parties as well as to the potential trial participants and are both unnecessary and avoidable.

Knowing your bottom-line position, understanding the rationale behind the other side's stance, recognizing the relative importance of the provision to each side, and making reasonable compromises under the circumstances can reduce stalemates, speed up the negotiation process, and get the trial site up and running much more quickly.

Not only that, but savvy sponsors and sites can capitalize on the momentum built during a successful CTA negotiation by using the final negotiated terms as a foundation for drafting a master clinical trial agreement. A master clinical trial agreement, or master CTA, eliminates time consuming negotiations in future trials and gets them running with little to no delay.



Ownership of trial data may be addressed in its own separate CTA provision or may be folded into another section, such as confidential information or intellectual property. Regardless of where it is located, ownership and use of trial data are sensitive topics for both sponsors and sites.

The Sponsor's Perspective: It is not uncommon for a sponsor to present the site with CTA language that gives the sponsor exclusive ownership of and unlimited right to use all data related to the site's participation in the trial. From the sponsor's viewpoint, its position is justified because it designed the trial protocol and paid the site for conducting the trial.

The Site's Perspective: The site will often respond that the sponsor is only entitled to own the data specifically contemplated by the protocol (e.g. case report forms (CRFs) and trial-specific test results) and that underlying original source documents, which document the existence of the participant and substantiate the integrity of the trial data collected (e.g., hospital records, clinical and office charts, laboratory notes, memoranda, participant diaries or evaluation checklists, pharmacy dispensing records, and microfilm or magnetic media, x-rays), are the property of the site. Additionally, the site will likely seek to limit the sponsor's use of the trial data. For instance, if the site is a non-profit entity, it may contend that it cannot conduct research on a work-for-hire basis and must be allowed to use trial data, including data that is owned by the sponsor for non-commercial research and education purposes and/or patient care.

The Compromise: Even the sponsor must acknowledge that a request to own all data related to the trial is too broad and reaches beyond what the sponsor actually needs to protect its interests and move the development of its product to the next stage. A properly drafted protocol will require that all necessary data end points be submitted to the sponsor on CRFs. The sponsor does not need the underlying source documents, a fact recognized by the International Conference on Harmonisation Harmonised Tripartite Guideline for Good Clinical Practice (ICH GCP) §8.3.13.

But it may need to audit the source documents at some point in the future, and will likely reserve its right to do so.

With respect to use of the trial data, the site should not object to the sponsor's use of it, provided such use is not prohibited by law and is authorized by the trial participants' informed consent and authorization documents. Similarly, the sponsor's interests are not infringed by granting the site the right to use trial data generated and contributed by the site for internal and non-commercial research, education, and/or patient care. Protection of all such rights is exemplified here:

Any and all information, documents, reports, data, results, and other information generated by Research Site pursuant to the Protocol that are required by the Protocol to be delivered to Sponsor and all copies thereof (collectively, the "Trial Results"), will be the property of Sponsor Subject to Trial Subjects' informed consent and authorization documents, Sponsor may use the Trial Results for any lawful purpose.

Notwithstanding the foregoing, the parties acknowledge and agree that the source documents, as defined in the Good Clinical Practice: Consolidated Guidelines published by the Food and Drug Administration, generated by Research Site and the data contained therein shall not be deemed Trial Results and are the exclusive property of Research Site; provided, however, that Sponsor shall have the right to inspect, audit, and/ or copy the source documents pursuant to this Agreement and subject to the informed consent and authorization documents.

Genetic Data: An Evolving Sub-set of Trial Data. As the field of personalized medicine continues to evolve, the ownership and use of biological specimens and the data derived therefrom pose new challenges to the negotiation of trial data ownership and use. Both sponsors and sites may seek to own and/or use specimens (e.g., blood or tissue samples) and the data derived from such specimens.

It is likely unnecessary for the sponsor to actually own the biological samples as long as the sponsor has the right to use the samples. The site should not object to the sponsor's use of the specimen provided such use does not violate applicable law and is authorized by the informed consent and authorization documents. If the sample is taken pursuant to the protocol, then it is reasonable for the sponsor to limit the site's use of the sample and any data derived therefrom to trial-related purposes. For example:

Sponsor shall have the right to possess, control, retain, store, use and dispose of biologic specimens collected pursuant to the protocol ("Specimens") in accordance with applicable laws and regulations to the extent authorized by the informed consent and authorization documents. Sponsor will own all protocol required data derived from the Specimens ("Specimen Data"). Sponsor will use Specimens or Specimen Data only to the extent not prohibited by applicable law, in accordance with the protocol, and subject to the informed consent form and authorization documents. Research Site will use Specimens and Specimen Data only for purposes of this Trial.


Disputes over ownership of trial-related intellectual property are similar to issues regarding ownership of trial data, but focus directly on who owns inventions or discoveries related to the investigational product or the trial in general.

The Sponsor's Perspective: The Sponsors will want broad language through which it owns all inventions, developments, discoveries, or improvements related to the trial or the investigational product.

The Site's Perspective: In the face of such broad language, the site will – almost without fail – object to the sponsor's language for its breadth. Additionally, the site may be unable to give away its intellectual property rights due to its non-profit status.

The Compromise: One way to span the gap between the sponsor and the site is to draft language that provides for site ownership of inventions created solely by the site and for joint ownership of inventions created by both the site and the sponsor. It will also be necessary to include language that gives the sponsor an option to negotiate a license for the site's interest in either or both. For example:

Any inventions or discoveries made by the Research Site in the performance of the Trial that: (i) are improvements, enhancements, or modifications to the Sponsor's Investigational Product; (ii) are new uses specific to the Sponsor's Investigational Product; (iii) incorporate Sponsor Confidential Information; or (iv) are anticipated by the Sponsor's protocols will be the sole property of Sponsor ("Sponsor Invention'')􀀀.

All inventions developed solely by the Research Site that are not sponsor Inventions shall be owned by Research Site ("Research Site Inventions"). All inventions that are not Sponsor Inventions that are developed by one or more employees of both Sponsor and Research Site under this Agreement shall be owned jointly by Sponsor and Research Site ("Joint Inventions")􀀀.

Sponsor shall have, without option fee, a timelimited, first option to negotiate an exclusive, worldwide, compensation-bearing license to any Research Site Invention and Research Site's rights in any Joint Invention. Sponsor shall advise Research Site in writing of its interest in obtaining an exclusive license to any Research Site Invention and/or Research Site's rights in any Joint Invention within sixty (60) days of Sponsor's receipt of notice of Research Site Invention and/or Joint Invention.


Publication issues most commonly arise between sponsors and academic institutions. Both sponsors and academic institutions want to publish trial results to share information about the clinical trial with the medical community and the public in a timely, accurate, and orderly manner; ensure the safety of the trial participants and the general public; advance science and medicine; meet regulatory obligations and industry guidelines; increase visibility; and promote their reputations within medical and scientific communities and with the general public. However, the independent publication goals of each party can result in a disagreement over CTA language.

The Sponsor's Perspective: The Sponsor prefers narrowly tailored language that ensures protection of its intellectual property and confidential information; facilitates multi-site coordination; safeguards the integrity of trial results, and furthers its competitive advantage.

The Site's Perspective: Sites are primarily focused on contributing to public knowledge; disclosing results for use in future research; and advancing its investigator's professional interests. The site will likely view the sponsor's language as an attempt to limit its academic freedom, interfere with its ability to publish data before other sites, and stymie its efforts to promote transparency and patient safety and education.

The Compromise: The key to resolving opposing interests can be resolved by making reasonable concessions on what information the site can publish, the timing of such publication, and the sponsor's ability to prevent publication of certain information. For example:

Research Site has the right to publish the results that it contributes and generates as a result of its Trial participation with due regard to the protection of Sponsor's Confidential Information provided that any such publication shall be delayed until the earlier of (i) the publication of the multi-center publication; (ii) notice from Sponsor that no multicenter publication will be forthcoming; or (iii) Twelve (12) months after the conclusion of the Trial all sites.

Research Site shall submit any proposed publication to Sponsor at least sixty (60) days before submission for publication. Sponsor will have the right to review and comment upon the publication in order to protect Sponsor Confidential Information and/ or Intellectual Property. Prior to releasing such publication, Research Site will delete Sponsor Confidential Information and Sponsor Intellectual Property. Upon Sponsor's request, publication will be delayed up to ninety (90) additional days to enable Sponsor to secure adequate intellectual property protection. Notwithstanding the foregoing, Sponsor cannot (i) require deletion of result generated and contributed by Research Site; (ii) require deletion of information needed to explain results and their scientific significance; or (iii) require deletions that make the publication incomplete, inaccurate, or misleading.


Trial participant injury is generally one of the most heavily negotiated provisions in a CTA. A sponsor is not legally required to cover medical expenses incurred in the treatment of a participant's injuries; however, most sponsors voluntarily agree to some level of reimbursement for medical expenses. While the parties generally agree that the reimbursement should be limited to medical expenses (i.e., not lost wages, pain and suffering, etc.), the sponsor's initial reimbursement offer usually falls short of what the site feels is adequate.

The Sponsor's Perspective: The sponsor's proposed injury reimbursement language usually requires that injury be directly caused by participation in the trial, provides that solely the sponsor will make the determination on causation, excludes certain intervening causes, and establishes a reasonable rate of reimbursement that is consistent with what would be paid outside of the context of the trial. Additionally, in an effort to reduce its financial risk, the sponsor may require that the site seek reimbursement of expenses from private insurers before seeking reimbursement from the sponsor.

The Site's Perspective: The site will likely remind the sponsor that since the sponsor is the ultimate beneficiary of the research, the sponsor's coverage of medical expenses should be as broad as possible. Consequently, the site will balk at narrowly tailored language, at attempts to exclude reimbursement – especially when predicated on the participant's behavior – and at disparate treatment based on the participant's insured status. Additionally, the site may have an issue with the determination of causation being solely the sponsor's call.

The Compromise: Once each side recognizes that the other party has valid and reasonable reasons driving its position on trial participant injury, compromises that serve the needs of both sponsor and site can easily be made. While some provisions will likely require a more thorough benefit/ risk analysis by the sponsor before concessions can be made, e.g., removing the requirement to file insurance and deleting the exclusion related to the trial participant's negligence or failure to follow instructions, the parties should be able to agree to:

  • tie the injury to the trial but make allowances for aggravation of pre-existing injuries;
  • mutual determination on causation or simply remain silent;
  • exclude reimbursement caused by the site's negligence (which is consistent with common law principles of liability); and
  • establish a rate of reimbursement equivalent to what an insurer would pay or negotiate a set flat rate acceptable to both parties.

Notwithstanding the foregoing, it is critical to note that, due to kick-back concerns, the terms agreed upon by the parties in the CTA cannot offer reimbursement beyond what the informed consent document promises to the trial participant.


To further reduce CTA negotiation time for future CTAs, sponsors and sites can capitalize on the momentum built during a successful CTA negotiation by using the final negotiated terms as a foundation for drafting a master clinical trial agreement.

A master clinical trial agreement, or MCTA, is an umbrella agreement between the sponsor and site where both parties agree upon a set of contractual terms and conditions for future clinical trials. Establishing a MCTA alleviates the need to re-negotiate the CTA's terms each time a new clinical trial is contemplated. Instead, a short and simple individual trial agreement is executed for each new trial. The individual trial agreement will incorporate the terms of the MCTA and set forth conditions specific to the particular study, such as protocol title, principal investigator name and budget.

While the MCTA will have some unique provisions, such as language describing the use of individual trial agreements and the term of the master agreement, the majority of the provisions should be comparable to the recently completed CTA. The parties may need to renegotiate if the MCTA will apply to a wider range of trial phases/investigational products or if additional levels of institutional review and comment may be required for master agreement. However, the vast majority of the prior language should be able to carry over into the MCTA, keeping negotiation time to an absolute minimum. As a result, trials can get up and running without delay.


Sponsors and clinical trial sites have a common interest in quickly negotiating clinical trials. By simply understanding the needs of the other party, recognizing where compromises can be made, and leveraging prior agreed upon language, the parties can effectively and efficiently eliminate CTA sticking points and quickly begin research activities.

To read this newsletter in full, please click here

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions